Overall, our study demonstrates that the CDK4/6-DUB3 axis contributes to the stabilization of YAP1, presenting an attractive therapeutic strategy in the treatment of HCC (Fig. 6M). The gene discussed is CDK4; the disease is hepatocellular carcinoma.